Glinix-M1 Forte Tablet SR is a combination oral antidiabetic medication containing Glimepiride 1mg and Metformin 1000mg in a sustained-release formulation. It is indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled by diet, exercise, and monotherapy with either agent. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. The sustained-release formulation ensures a gradual release of active ingredients, promoting better glycemic control with reduced gastrointestinal side effects commonly associated with immediate-release metformin. Glinix-M1 Forte Tablet SR should be administered once daily with meals to minimize adverse effects and optimize absorption. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Dose adjustments may be necessary based on therapeutic response and tolerability. This combination therapy offers a synergistic approach to glycemic control, improving patient compliance and reducing the risk of diabetes-related complications.